Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are widely used in Italy to treat respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis. The market for bronchodilator drugs in Italy has been experiencing steady growth over the years.
Customer preferences: The Italian market for bronchodilator drugs is driven by the increasing prevalence of respiratory diseases, especially among the aging population. Patients prefer the use of inhalers over oral medications due to their convenience and effectiveness in delivering medication directly to the lungs. Additionally, the preference for combination therapy, which involves using two or more bronchodilator drugs, has been increasing in Italy.
Trends in the market: The bronchodilator drugs market in Italy has been experiencing a shift towards the use of long-acting beta-agonists (LABA) and long-acting muscarinic antagonists (LAMA). The use of LABA/LAMA combination therapy has been increasing due to its effectiveness in treating COPD. Moreover, the market has been witnessing the introduction of new bronchodilator drugs with improved efficacy and safety profiles.
Local special circumstances: The Italian government has been implementing measures to control healthcare expenditure, which has affected the bronchodilator drugs market. The government has been promoting the use of generic drugs to reduce healthcare costs, which has led to increased competition among drug manufacturers. Additionally, the Italian pharmaceutical market is highly regulated, and drug prices are subject to negotiation with the government.
Underlying macroeconomic factors: The aging population in Italy has been a major driver of the bronchodilator drugs market. The prevalence of respiratory diseases increases with age, and the aging population in Italy has been growing rapidly. Additionally, the Italian healthcare system provides universal healthcare coverage, which has led to increased access to healthcare services, including bronchodilator drugs. The Italian economy has been recovering from the recession, which has led to increased healthcare spending and improved access to healthcare services.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
